A review of research endeavors to optimize peripheral nerve reconstruction.
This manuscript reviews studies relating to peripheral nerve allografts, neuroregenerative agents and end-to-side neurorrhaphy. With respect to peripheral nerve allografts, animal studies with the agents cyclosporin A, FK506 and rapamycin are reviewed and related to recent clinical experience. FK506 distinguishes itself as an agent capable of reversing acute rejection of a peripheral nerve allograft and an agent with some neuroregenerative properties. In addition to systemic immunosuppression, experience with agents purported to initiate a state of donor specific tolerance are discussed. Specifically, experimental studies with administration of ultraviolet B treated donor splenocytes, antibodies to cellular adhesion molecules and antibodies to components of the costimulatory pathway of immunosuppression are reviewed. The neuroregenerative properties of FK506 and related compounds are examined in animal models. Finally, the experimental finding that reinnervation following end-to-side neurorrhaphy is mostly sensory and related to the degree of axonal damage at the level of an epineurotomy or perineurotomy is discussed.
Myckatyn
Terence M
TM
Division of Plastic and Reconstructive Surgery, Washington University School of Medicine, Suite 17424 East Pavilion, I Barnes-Jewish Hospital Plaza, St Louis, Missouri, MI, USA.
Mackinnon
Susan E
SE
D000818:Animals; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D010525:Peripheral Nerves / Q000502:physiology* / Q000637:transplantation*; D019651:Plastic Surgery Procedures / Q000379:methods; D012107:Research Design / Q000592:standards; D014184:Transplantation, Homologous